Table 4.
The correlation of CDK5 with diverse clinical clinicopathological factors in NSCLC
| NSCLC | n | CDK5 negative (n, %) | CDK5 positive (n, %) | Z | P |
|---|---|---|---|---|---|
| Gender | −0.406 | 0.685 | |||
| Male | 254 | 126(49.6) | 128(50.4) | ||
| Female | 85 | 40(47.1) | 45(52.9) | ||
| Age(years) | −0.080 | 0.936 | |||
| <60 | 181 | 89(49.2) | 92(50.8) | ||
| ≥60 | 158 | 77(48.7) | 81(51.3) | ||
| Pathological grading | 24.58a | <0.001 | |||
| I | 39 | 29(74.4) | 10(25.6) | ||
| II | 92 | 53(57.6) | 39(42.4) | ||
| III | 130 | 44(33.8) | 86(66.2) | ||
| TNM | −2.376 | 0.018 | |||
| I–II | 286 | 148(51.7) | 138(48.3) | ||
| III–IV | 53 | 18(34.0) | 35(66.0) | ||
| LNM | −6.717 | <0.001 | |||
| Yes | 115 | 27(23.5)) | 88(76.5) | ||
| No | 224 | 139(62.1) | 85(37.9) | ||
| Tumor diameter (cm) | −1.145 | 0.252 | |||
| ≤7 | 295 | 148(50.2) | 147(49.8) | ||
| >7 | 44 | 18(40.9) | 26(59.1) | ||
| Distal metastasis | −1.962 | 0.05 | |||
| Absent | 323 | 162(50.2) | 161(49.8) | ||
| Present | 16 | 4(25.0) | 12(75.0) | ||
| Histology | 3.646a | 0.456 | |||
| Adenocarcinoma | 127 | 64(50.4) | 63(49.6) | ||
| Squamous cell carcinoma | 175 | 88(50.3) | 87(49.7) | ||
| Adenosquamous carcinoma | 28 | 10(35.7) | 18(64.3) | ||
| Undifferentiated carcinoma | 8 | 3(37.5) | 5(62.5) | ||
| Large cell carcinoma | 1 | 1(100) | 0(0) | ||
| Adenocarcinoma classification | 6.508a | 0.089 | |||
| Acinar adenocarcinoma | 83 | 36(43.4) | 47(56.6) | ||
| Papillary adenocarcinoma | 19 | 12(63.2) | 7(36.8) | ||
| Broncholoalveolar cell carcinoma | 18 | 10(55.6) | 8(44.4) | ||
| Mucinous carcinoma | 7 | 6(85.7) | 1(14.3) |
Pathological grading I vs. II Z = −1.805, P = 0.071, I vs. III Z = −4.466, P < 0.001, II vs. III Z = −3.508, P < 0.001. Acinar adenocarcinoma vs. mucinous Z = −2.144, P = 0.032. There were no differences of expression of CDK5 in other subgroups
aKruskal-Wallis H test was performed when the data were divided into more than two groups